Mr Joachim Torrano
Casual Senior Research Technician
The University of Queensland Diamantina Institute
Journal Articles
Rutjes, Chantal, Torrano, Joachim and Soyer, H. Peter (2022). A 3D total-body photography research network: the Australian experiment. Der Hautarzt, 73 (3), 236-240. doi: 10.1007/s00105-021-04938-7
Menon, Dinoop Ravindran, Hammerlindl, Heinz, Torrano, Joachim, Schaider, Helmut and Fujita, Mayumi (2020). Epigenetics and metabolism at the crossroads of stress-induced plasticity, stemness and therapeutic resistance in cancer. Theranostics, 10 (14), 6261-6277. doi: 10.7150/thno.42523
Torrano, Joachim, Al Emran, Abdullah, Hammerlindl, Heinz and Schaider, Helmut (2019). Emerging roles of H3K9me3, SETDB1 and SETDB2 in therapy-induced cellular reprogramming. Clinical Epigenetics, 11 (1) 43, 43. doi: 10.1186/s13148-019-0644-y
Hammerlindl, Heinz, Ravindran Menon, Dinoop, Hammerlindl, Sabrina, Emran, Abdullah Al, Torrano, Joachim, Sproesser, Katrin, Thakkar, Divya, Xiao, Min, Atkinson, Victoria G., Gabrielli, Brian, Haass, Nikolas K., Herlyn, Meenhard, Krepler, Clemens and Schaider, Helmut (2018). Acetylsalicylic acid governs the effect of sorafenib in RAS- mutant cancers. Clinical Cancer Research, 24 (5), 1090-1102. doi: 10.1158/1078-0432.CCR-16-2118
Emran, Abdullah Al, Marzese, Diego M., Menon, Dinoop Ravindran, Stark, Mitchell S., Torrano, Joachim, Hammerlindl, Heinz, Zhang, Gao, Brafford, Patricia, Salomon, Matthew P., Nelson, Nellie, Hammerlindl, Sabrina, Gupta, Deepesh, Mills, Gordon B., Lu, Yiling, Sturm, Richard A., Flaherty, Keith, Hoon, Dave S. B., Gabrielli, Brian, Herlyn, Meenhard and Schaider, Helmut (2017). Distinct histone modifications denote early stress-induced drug tolerance in cancer. Oncotarget, 9 (9), 8206-8222. doi: 10.18632/oncotarget.23654
Conference Papers
Menon, D. Ravindran, Hammerlindl, H., Emran, A., Torrano, J., Hammerlindl, S., Zhang, G., Krause, L., Somasundaram, R., Sturm, R., Haass, N. K., Flaherty, K., Herlyn, M. and Schaider, H. (2018). Escape form adaptive drug tolerance through OGT and TET1 mediated H3K4me3 remodeling in MAPKi-resistant melanoma. International Investigative Dermatology (IID) Meeting, Orlando, Fl, United States, 16-19 May 2018. London, United Kingdom: Nature Publishing Group. doi: 10.1016/j.jid.2018.03.1252
Menon, Dinoop Ravindran, Hammerlindl, Heinz, Al Emran, Abdullah, Torrano, Joachim, Hammerlindl, Sabrina, Zhang, Gao, Somasundaram, Rajasekharan, Sturm, Richard A., Haass, Nikolas K., Flaherty, Keith, Herlyn, Meenhard and Schaider, Helmut (2018). Escape form adaptive drug tolerance through OGT and TET1 mediated H3K4me3 remodeling in MAPKi resistant melanoma. Annual Meeting of the American Association for Cancer Research (AACR), Chicago, IL United States, 14-18 April 2018. Philadelphia, PA United States: American Association of Cancer Research. doi: 10.1158/1538-7445.AM2018-5833
Emran, A., Marzese, D. M., Menon, D. R., Stark, M., Torrano, J., Hammerlindl, H., Zhang, G., Brafford, P., Hammerlindl, S., Gupta, D., Mills, G. B., Lu, Y., Flaherty, K., Sturm, R., Hoon, D. S. B., Gabrielli, B., Herlyn, M. and Schaider, H. (2018). Distinct epigenetic remodelling defines early stress-induced drug tolerance in melanoma. Australasian College of Dermatologists, 51st Annual Scientific Meeting, Gold Coast, QLD, Australia , 19–22 May 2018. Richmond, VIC, Australia: Wiley-Blackwell Publishing. doi: 10.1111/ajd.16_12815
Thesis
Torrano, Joachim (2020). The role of SETDB1/2-mediated H3K9me3 in drug-tolerant cancer. MPhil Thesis, Faculty of Medicine, The University of Queensland. doi: 10.14264/uql.2020.717